Feed BMY
BM

Bristol-Myers Squibb

BMY · NYSE

$63.04 +0.32% (+$0.20)
1M -5.89%
Market Cap $128.3B
P/E Ratio 13.83x
Div. Yield 3.99%
ROE 46.75%

Bulios Fair Price

$52.55

16.6% downside

Trenutna cena

$63.04

Podcenjeno Poštena vrednost Precenjeno

Po podatkih Bulios Fair Price je delnica BMY trenutno precenjena glede na svojo tržno ceno. Kako deluje?

Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?

Piotroski F-Score Strong
7/9
Valuation
79 /100
Cheap
P/E 13.83x
EV/EBITDA 9.76x
P/S 2.61x
Growth
31 /100
Declining
EPS growth 5.36%
Rev. growth 1.45%
FCF growth 2.44%
Profitability
100 /100
Strong
Gross margin 70.16%
Net margin 18.87%
Op. margin 28.27%
Quality
83 /100
Excellent
ROIC 15.47%
ROE 46.75%
ROA 10.59%
Debt
54 /100
Moderate
Debt/Equity 1.93x
Current ratio 1.53x
Int. coverage 7.88x
Stability
35 /100
Moderate
Beta 0.23x
Rev. volatility 5.14%
EPS volatility 198.26%

Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več

Vprašajte StockBota o BMY
Online

O podjetju

Bristol-Myers Squibb Company (BMY) is an American pharmaceutical company with a global reach. The company specializes in research, development, and manufacturing of drugs and biological products for the treatment of various diseases. Bristol-Myers Squibb focuses its efforts on the treatment of cancer, cardiovascular diseases, immune disorders, and other serious conditions. The company is known for its innovative medications that bring significant medical benefits to patients. Bristol-Myers Squibb has a wide range of drugs on the market, and its products are distributed worldwide. The company also has an active research program aimed at discovering new drugs and therapeutic approaches. Bristol-Myers Squibb Company (BMY) shares are an attractive choice for investors who follow the pharmaceutical sector and seek investment opportunities in a renowned pharmaceutical company with a focus on innovative treatment methods.

V vašem jeziku še ni na voljo, zato je besedilo v angleščini.

Sector

Healthcare

Industry

Drug Manufacturers - General

CEO

Christopher Boerner

Employees

32,500

Headquarters

Princeton

Prihajajoči dogodki

02 OKT.

Ex-Dividend

Ex-dividend date

12d
29 OKT.

Earnings

Upcoming earnings report

39d
02 NOV.

Dividend Payment

Datum plačila

43d

Uporabljamo nujne piškotke za delovanje spletnega mesta in izbirne analitične piškotke za merjenje uporabe. Preberite naš Pravilnik o zasebnosti.